Gulf Coast Consortia (GCC) Research Evaluation and Commercialization Hub

In recent years, the NIH has awarded over $850M annually to the numerous research institutions and hospitals within the Texas Medical Center (TMC; Houston, TX), producing ever-increasing numbers of biomedical discoveries. Despite this massive investment, only some of these discoveries advance to the clinic, and even fewer are successfully commercialized to improve patient health and well-being. Texas academic entrepreneurs face significant challenges as they seek to commercialize their discoveries, including a lack of training and resources to support early- stage business and technology development. To address these deficiencies, we will establish the Gulf Coast Consortium Research Evaluation and Commercialization Hub (GCC-REACH) as an integrated multi-institutional resource wherein nascent academic entrepreneurs work closely with successful life science experts and experienced biotech executives to develop strategic milestone-driven timelines to rapidly validate the commercial value of their discoveries. GCC-REACH will expand the GCC and TMC infrastructure and resources we have designed to support emerging biomedical companies. Academic entrepreneurs will hail from all GCC-affiliated institutions (Baylor College of Medicine, Texas A&M Health Science Center, Houston Methodist Research Institute, MD Anderson Cancer Center, Rice University, Texas Southern University, University of Houston, the University of Texas Health Science Center, University of Texas Medical Branch) as well as other academic and research institutions across Texas, extending beyond Houston. The GCC-REACH program will provide managerial oversight, access to vetted resources, and seed funds to assist each entrepreneur in progressing to a clear value-added commercialization inflection point. Significance: Discussions with numerous Texas-based researchers, all GCC-affiliated technology transfer offices, successful life science companies, and healthcare investors have indicated widespread support for this initiative, noting that it would help launch new companies and advance biomedical discoveries. Importantly, GCC-REACH will pair entrepreneurs who balance full-time clinical, teaching, and laboratory duties with EIRs and expert teams who will provide mentorship and assistance in completing the market analysis, business plans, and technology development strategies. Value proposition: In combination with substantial multi-institutional support, NIH's $4M investment will enable GCC-REACH to train academic entrepreneurs to successfully commercialize novel discoveries. We expect these entrepreneurs will launch approximately 60 highly-competitive early-stage biomedical companies that will be highly competitive for non-dilutive NIH SBIR/STTR funding and venture investment.